Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 22616830)

1.

Drotrecogin alfa (activated) in adults with septic shock.

Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group.

N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22.

2.

A dream deferred: the rise and fall of recombinant activated protein C.

Holder AL, Huang DT.

Crit Care. 2013 Mar 12;17(2):309. doi: 10.1186/cc12533.

3.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

4.

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

Crit Care Med. 2004 Nov;32(11):2199-206.

PMID:
15640631
5.

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

Crit Care. 2008;12(2):R45. doi: 10.1186/cc6854. Epub 2008 Apr 4. Review.

6.

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.

Lancet. 2007 Mar 10;369(9564):836-43.

PMID:
17350452
7.

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.

Spapen H, Nguyen DN, Troubleyn J, Huyghens L, Schiettecatte J.

Crit Care. 2010;14(2):R54. doi: 10.1186/cc8947. Epub 2010 Apr 7.

8.

Efficacy and safety of recombinant human activated protein C for severe sepsis.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.

N Engl J Med. 2001 Mar 8;344(10):699-709.

9.

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

PMID:
17084715
10.

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

Surgery. 2007 Apr;141(4):548-61.

PMID:
17431957
11.

Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.

Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, Siami S, Chagnon JL, Constantin JM, Petitpas F, Souweine B, Amathieu R, Forceville X, Charpentier C, Tesnière A, Chastre J, Bohe J, Colin G, Cariou A, Renault A, Brun-Buisson C, Bellissant E; APROCCHSS Trial Investigators.

Am J Respir Crit Care Med. 2013 May 15;187(10):1091-7. doi: 10.1164/rccm.201211-2020OC.

PMID:
23525934
12.

Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.

Póvoa P, Salluh JI, Martinez ML, Guillamat-Prats R, Gallup D, Al-Khalidi HR, Thompson BT, Ranieri VM, Artigas A.

Crit Care. 2015 Apr 28;19:193. doi: 10.1186/s13054-015-0921-x.

13.

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated).

Levy H, Laterre PF, Bates B, Qualy RL.

Crit Care. 2005 Oct 5;9(5):R502-7. Epub 2005 Jul 27.

14.

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.

PMID:
17556722
15.

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

Crit Care Med. 2004 Nov;32(11):2207-18.

PMID:
15640632
16.

Human recombinant activated protein C for severe sepsis.

Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD004388. doi: 10.1002/14651858.CD004388.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD004388.

PMID:
22419295
17.

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

Crit Care Med. 2005 May;33(5):952-61.

PMID:
15891319
18.

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.

Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D.

Intensive Care Med. 2007 Mar;33(3):426-34. Epub 2007 Feb 15.

PMID:
17325836
19.

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

Barie PS, Hydo LJ, Shou J, Eachempati SR.

Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

PMID:
16895513
20.

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.

PMID:
18158435
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk